Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II.
- Author:
Young Joon HONG
1
;
Myung Ho JEONG
;
Jang Ho BAE
;
Seok Kyu OH
;
Seung Woon RHA
;
Seung Ho HUR
;
Sung Yun LEE
;
Sang Wook KIM
;
Kwang Soo CHA
;
In Ho CHAE
;
Tae Hoon AHN
;
Kee Sik KIM
Author Information
- Publication Type:Original Article
- Keywords: Myocardial infarction; Atherosclerosis; Lipids; Hydroxymethylglutaryl-CoA reductase inhibitors
- MeSH: Angina, Unstable; Atherosclerosis; Blood Glucose; Cholesterol, LDL; Death; Fasting; Follow-Up Studies; Glucose; Heart Failure; Hemoglobin A, Glycosylated; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction*
- From:The Korean Journal of Internal Medicine 2017;32(4):656-667
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. METHODS: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. RESULTS: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). CONCLUSIONS: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.
